RJA
GALT icon

Raymond James & Associates’s Galectin Therapeutics GALT Stock Holding History

Raymond James & Associates’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,096
Closed -$51K – 4197
2021
Q3 		$51K Buy
+13,096
New +$44.4K ﹤0.01% 3914
2020
Q4 		– Sell
-27,740
Closed -$74K – 3810
2020
Q3 		$74K Hold
27,740
– – ﹤0.01% 3412
2020
Q2 		$85K Hold
27,740
– – ﹤0.01% 3320
2020
Q1 		$54K Hold
27,740
– – ﹤0.01% 3305
2019
Q4 		$79K Buy
27,740
+650
+2% +$2.26K ﹤0.01% 3505
2019
Q3 		$99K Buy
+27,090
New +$97.9K ﹤0.01% 3390
2018
Q1 		– Sell
-18,090
Closed -$60K – 3499
2017
Q4 		$60K Buy
+18,090
New +$45.7K ﹤0.01% 3265

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's GALT Position: Q4 2021 in Review

Raymond James & Associates sold out of Galectin Therapeutics (GALT) in Q4 2021, closing a stake of 13,096 shares — an estimated $51K sold.

Raymond James & Associates first reported a position in GALT in Q4 2017 and held it in 7 quarters. The position peaked at $99K in Q3 2019. 55 funds tracked by Wall St. Rank hold GALT as of Q4 2021.

  • Raymond James & Associates reported no remaining Galectin Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 13,096 Galectin Therapeutics shares in Q4 2021, an estimated $51K.
  • Raymond James & Associates first reported a position in Galectin Therapeutics in Q4 2017 and held it in 7 quarters.
  • Raymond James & Associates's Galectin Therapeutics position peaked at $99K in Q3 2019.
  • 55 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.